Agnieszka Boesen

Array ( [id] => 12769984 [patent_doc_number] => 20180148496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => ANTI-PRE-S1 HBV ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/864494 [patent_app_country] => US [patent_app_date] => 2018-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7123 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15864494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17074892 [patent_doc_number] => 11111277 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-07 [patent_title] => Influenza vaccines [patent_app_type] => utility [patent_app_number] => 15/857436 [patent_app_country] => US [patent_app_date] => 2017-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 8 [patent_no_of_words] => 38229 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15857436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15145133 [patent_doc_number] => 20190351044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => LASSA VIRUS VACCINE [patent_app_type] => utility [patent_app_number] => 16/471544 [patent_app_country] => US [patent_app_date] => 2017-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16471544 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15145139 [patent_doc_number] => 20190351047 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => HENIPAVIRUS VACCINE [patent_app_type] => utility [patent_app_number] => 16/471541 [patent_app_country] => US [patent_app_date] => 2017-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79243 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16471541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12641268 [patent_doc_number] => 20180105587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => BINDING MOLECULES TARGETING PATHOGENS [patent_app_type] => utility [patent_app_number] => 15/851272 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12701 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15851272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14994223 [patent_doc_number] => 20190316069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => ANTIGEN PRESENTING SCAFFOLDS FOR IMMUNE-CELL MANIPULATION [patent_app_type] => utility [patent_app_number] => 16/470503 [patent_app_country] => US [patent_app_date] => 2017-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19977 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16470503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12808747 [patent_doc_number] => 20180161419 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => METHODS FOR IMPROVING THE EFFICACY OF VACCINE ANTIGENS [patent_app_type] => utility [patent_app_number] => 15/847694 [patent_app_country] => US [patent_app_date] => 2017-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13291 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15847694 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18051623 [patent_doc_number] => 11524994 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-13 [patent_title] => Antibodies to human respiratory syncytial virus protein F pre-fusion conformation and methods of use therefor [patent_app_type] => utility [patent_app_number] => 16/470604 [patent_app_country] => US [patent_app_date] => 2017-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 21 [patent_no_of_words] => 23394 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16470604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14273801 [patent_doc_number] => 20190134185 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => UNIVERSAL INFLUENZA VACCINE BASED ON HETEROLOGOUS MULTIPLE M2E PROTEINS [patent_app_type] => utility [patent_app_number] => 15/841556 [patent_app_country] => US [patent_app_date] => 2017-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15841556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16013671 [patent_doc_number] => 20200181678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => Cell-Based Reporter Assay for Live Virus Vaccines [patent_app_type] => utility [patent_app_number] => 16/468798 [patent_app_country] => US [patent_app_date] => 2017-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6590 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16468798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17800394 [patent_doc_number] => 11414679 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-16 [patent_title] => Adenovirus polynucleotides and polypeptides [patent_app_type] => utility [patent_app_number] => 16/466683 [patent_app_country] => US [patent_app_date] => 2017-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 15 [patent_no_of_words] => 20542 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16466683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14893971 [patent_doc_number] => 20190290751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => MARBURGVIRUS CONSENSUS ANTIGENS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME [patent_app_type] => utility [patent_app_number] => 16/465691 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18465 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16465691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13970767 [patent_doc_number] => 10214726 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-26 [patent_title] => Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject [patent_app_type] => utility [patent_app_number] => 15/821523 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 46 [patent_no_of_words] => 41361 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15821523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17680063 [patent_doc_number] => 11364294 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-21 [patent_title] => Vaccine compositions having improved stability and immunogenicity [patent_app_type] => utility [patent_app_number] => 15/819962 [patent_app_country] => US [patent_app_date] => 2017-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 103 [patent_figures_cnt] => 104 [patent_no_of_words] => 24015 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15819962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16009329 [patent_doc_number] => 20200179507 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => IMMORTALIZED CELL LINES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/461222 [patent_app_country] => US [patent_app_date] => 2017-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5422 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16461222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17554956 [patent_doc_number] => 11311613 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Development of agonist epitopes of the human papillomavirus [patent_app_type] => utility [patent_app_number] => 16/347764 [patent_app_country] => US [patent_app_date] => 2017-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13223 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16347764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14016483 [patent_doc_number] => 20190070235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => METHOD FOR TREATING HEPATITIS B [patent_app_type] => utility [patent_app_number] => 15/782671 [patent_app_country] => US [patent_app_date] => 2017-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1700 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15782671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15381817 [patent_doc_number] => 10532067 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-14 [patent_title] => Delivery of RNA to trigger multiple immune pathways [patent_app_type] => utility [patent_app_number] => 15/725858 [patent_app_country] => US [patent_app_date] => 2017-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 19 [patent_no_of_words] => 16543 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15725858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12580746 [patent_doc_number] => 20180085411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/716974 [patent_app_country] => US [patent_app_date] => 2017-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20238 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15716974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18215304 [patent_doc_number] => 11590218 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-28 [patent_title] => Generation of HPV-specific T-cells [patent_app_type] => utility [patent_app_number] => 16/333597 [patent_app_country] => US [patent_app_date] => 2017-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 18571 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16333597 [rel_patent_id] =>[rel_patent_doc_number] =>)